Securities Code: 4506

# Supplementary Financial Data (IFRS) for the Year Ended March 31, 2026


| | | |
|---|---|---|
| I. | Consolidated Financial Highlights | 1 |
| II. | Consolidated Statement of Profit or Loss | 3 |
| III. | Segment Information | 4 |
| IV. | Revenue Information | 5 |
| V. | Gross Profit by Region | 7 |
| VI. | Consolidated Statement of Financial Position | 8 |
| VII. | Changes in Quarterly Results | 9 |
| VIII. | Major Group Companies | 10 |
| IX. | Shareholder Positioning | 11 |
| X. | Development Pipeline | 12 |
| XI. | Profiles of Major Products under Development | 13 |


**May 13, 2026**

Sumitomo Pharma Co., Ltd.

- This material contains forecasts, projections, goals, plans, and other forward-looking statements regarding the Group's financial results and other data. Such forward-looking statements are based on the Company's assumptions, estimates, outlook, and other judgments made in light of information available at the time of disclosure of such statements and involve both known and unknown risks and uncertainties. Accordingly, due to various subsequent factors, forecasts, plans, goals, and other statements may not be realized as described, and actual financial results, success/failure or progress of development, and other projections may differ materially from those presented herein.
- Information concerning pharmaceuticals and other products (including those under development) contained herein is not intended as advertising or as medical advice.
- All values are rounded. Therefore totals may not be consistent with aggregated figures.

## I. Consolidated Financial Highlights

### 1. Consolidated Statement of Profit or Loss (Core Basis)

(Billions of JPY)

| | FY2024 | FY2025 | Change % | FY2026 (Forecasts) | Change % YoY |
|---|---|---|---|---|---|
| **Revenue** | 398.8 | **453.3** | 13.7 | 540.0 | 19.1 |
| Cost of sales *1 | 153.2 | **196.4** | 28.2 | 245.0 | 24.7 |
| Gross profit | 245.6 | **256.9** | 4.6 | 295.0 | 14.8 |
| SG&A expenses *1 | 167.7 | **159.3** | (5.0) | 155.0 | (2.7) |
| R&D expenses *1 | 48.5 | **43.9** | (9.4) | 51.0 | 16.0 |
| Others (core basis) *2 | 13.7 | **52.3** | | 2.0 | |
| **Core operating profit** | 43.2 | **105.9** | 145.4 | 91.0 | (14.1) |
| Adjustments *3 (negative number indicates net expense) | (14.3) | **1.4** | | (1.0) | |
| **Operating profit** | 28.8 | **107.3** | 272.6 | 90.0 | (16.2) |
| **Net profit attributable to owners of the parent** | 23.6 | **106.9** | 352.2 | 77.0 | (27.9) |
| Basic earnings per share (JPY) | 59.49 | **268.99** | | 172.89 | |
| Net profit/ Equity attributable to owners of the parent (ROE) | 14.5% | **46.3%** | | 20.3% | |
| Return on invested capital (ROIC) | 9.4% | **22.8%** | | 15.1% | |

### 2. Consolidated Statement of Profit or Loss (Full Basis)

(Billions of JPY)

| | FY2024 | FY2025 | Change % |
|---|---|---|---|
| **Revenue** | 398.8 | **453.3** | 13.7 |
| Cost of sales | 153.4 | **196.4** | 28.0 |
| Gross profit | 245.4 | **256.9** | 4.7 |
| SG&A expenses | 180.6 | **162.6** | (10.0) |
| R&D expenses | 49.9 | **44.0** | (11.8) |
| Other operating income/expenses, etc. | 13.9 | **57.0** | |
| **Operating profit** | 28.8 | **107.3** | 272.6 |
| Finance income/costs | (11.2) | **(7.0)** | |
| **Profit before taxes** | 17.6 | **100.3** | 469.8 |
| Income tax expenses | (6.0) | **(6.5)** | |
| **Net profit attributable to owners of the parent** | 23.6 | **106.9** | 352.2 |

*1 Exclude adjustments
*2 Including P/L on business transfers, share of P/L of associates accounted for using equity method
*3 Impairment loss, business structure improvement expenses, and changes in fair value of contingent consideration, etc.

### 3. Consolidated Statement of Cash Flows

(Billions of JPY)

| | FY2024 | FY2025 |
|---|---|---|
| Net cash provided by (used in) operating activities | 16.5 | **71.7** |
| Net cash provided by (used in) investing activities | 99.8 | **22.5** |
| Net cash provided by (used in) financing activities | (108.8) | **(91.3)** |
| Cash and cash equivalents at the end of period | 23.1 | **44.3** |

### 4. Foreign Exchange Rates

| | Period end rate | | Average rate | | FY2026 assumption | Forex sensitivity FY2026 (Impact of JPY depreciation by ¥1) | |
|---|---|---|---|---|---|---|---|
| | Mar. 31 2025 | **Mar. 31 2026** | FY2024 Apr.-Mar. | **FY2025 Apr.-Mar.** | **Average rate** | Revenue | Core operating profit |
| JPY / USD | 149.53 | **159.90** | 152.62 | **150.67** | **155.00** | 2.8 | 0.6 |
| JPY / RMB | 20.59 | **20.74** | 21.11 | **20.12** | - | - | - |

(Billions of JPY)

(Billions of JPY)

| **5. Capital Expenditures/ Depreciation and Amortization** | FY2024 | **FY2025** | Change | FY2026 (Forecasts) | Change YoY |
|---|---|---|---|---|---|
| Capital expenditures | 12.1 | **6.6** | (5.5) | 8.0 | 1.4 |
| Depreciation of property, plant and equipment | 8.3 | **6.7** | (1.6) | 5.9 | (0.8) |
| Amortization of intangible assets | 17.3 | **14.0** | (3.3) | 13.7 | (0.3) |
| Related to products (patent rights/ marketing rights) included in above | 15.0 | **12.4** | (2.6) | 12.3 | (0.1) |

Note: The amount of capital expenditures are for tangible fixed assets and software.

## II. Consolidated Statement of Profit or Loss

### 1. Consolidated Statement of Profit or Loss (Core Basis)

(Billions of JPY)

| | FY2024 | FY2025 | Change | Change % |
|---|---|---|---|---|
| **Revenue** | 398.8 | **453.3** | 54.5 | 13.7 |
| Overseas revenue | 306.9 | **369.9** | 63.0 | 20.5 |
| % of Revenue | 76.9% | **81.6%** | | |
| Cost of sales | 153.2 | **196.4** | 43.2 | 28.2 |
| % of Revenue | 38.4% | **43.3%** | | |
| **Gross profit** | 245.6 | **256.9** | 11.2 | 4.6 |
| SG&A expenses | 167.7 | **159.3** | (8.4) | (5.0) |
| Labor costs | 78.9 | **76.9** | (2.0) | (2.6) |
| Sales promotion/ Advertising costs | 25.0 | **21.4** | (3.6) | (14.5) |
| Amortization/Depreciation | 20.1 | **16.5** | (3.6) | (18.1) |
| Others | 43.7 | **44.6** | 0.9 | 2.1 |
| R&D expenses | 48.5 | **43.9** | (4.5) | (9.4) |
| % of Revenue | 12.2% | **9.7%** | | |
| Others (core basis) | 13.7 | **52.3** | 38.6 | |
| **Core operating profit** | 43.2 | **105.9** | 62.8 | 145.4 |
| Adjustments (negative number indicates net expense) | (14.3) | **1.4** | 15.8 | |
| **Operating profit** | 28.8 | **107.3** | 78.5 | 272.6 |
| Finance income | 2.3 | **3.2** | 0.9 | |
| Finance costs | 13.5 | **10.2** | (3.3) | |
| **Profit before taxes** | 17.6 | **100.3** | 82.7 | 469.8 |
| Income tax expenses | (6.0) | **(6.5)** | (0.5) | |
| **Net profit attributable to owners of the parent** | 23.6 | **106.9** | 83.2 | 352.2 |

| | Change | FX impact |
|---|---|---|
| Japan | (7.5) | |
| North America | 86.1 | (4.5) |
| Asia | (24.2) | (0.8) |

Change by segment

| | Japan | North America | Asia |
|---|---|---|---|
| Labor costs | (1.9) | 3.9 | (4.0) |
| Sales promotion/ Advertising costs | (1.0) | (1.8) | (0.8) |
| Amortization/ Depreciation | (1.4) | (1.8) | (0.4) |
| Others | (2.4) | 6.0 | (2.7) |

FY25: Gains on partial transfer of the Asian business +49.0

FY24: Impairment loss (5.5)
Business structure improvement expenses in Japan (5.9)
Business structure improvement expenses in North America (2.9)
FY25: Impairment loss in North America (2.1)
Changes in fair value of contingent consideration +3.2

### 2. Adjustments to Core Operating Profit

(Billions of JPY)

| FY2025 Results | Full Basis | Core Basis | Adjustment | Major adjustment items |
|---|---|---|---|---|
| **Revenue** | 453.3 | **453.3** | — | |
| Cost of sales | 196.4 | **196.4** | — | |
| **Gross profit** | 256.9 | **256.9** | — | |
| SG&A expenses | 162.6 | **159.3** | (3.2) | Impairment loss in North America (2.1) |
| R&D expenses | 44.0 | **43.9** | (0.0) | |
| Other operating income/expenses, etc. | 57.0 | **52.3** | (4.7) | Changes in fair value of contingent consideration (3.1)<br>Gain on reversal of impairment loss in North America (1.1) |
| **Operating profit** | 107.3 | **105.9** | (1.4) | |

## III. Segment Information (Core Basis)

(Billions of JPY)

| FY2025 Results | Japan | North America | Asia | Total |
|---|---|---|---|---|
| Revenue | 92.4 | 337.9 | 23.0 | 453.3 |
| Cost of sales | 50.1 | 137.4 | 8.8 | 196.4 |
| Gross profit | 42.2 | 200.5 | 14.2 | 256.9 |
| SG&A expenses | 29.9 | 124.7 | 4.7 | 159.3 |
| **Core segment profit** | **12.4** | **75.7** | **9.5** | **97.5** |
| R&D expenses *1 | | | | 43.9 |
| Others (core basis) *2 | | | | 52.3 |
| **Core operating profit** | | | | **105.9** |

(Billions of JPY)

| FY2024 Results | Japan | North America | Asia | Total |
|---|---|---|---|---|
| Revenue | 99.8 | 251.8 | 47.2 | 398.8 |
| Cost of sales | 51.8 | 90.8 | 10.6 | 153.2 |
| Gross profit | 48.0 | 161.0 | 36.6 | 245.6 |
| SG&A expenses | 36.6 | 118.4 | 12.7 | 167.7 |
| **Core segment profit** | **11.4** | **42.6** | **23.9** | **77.9** |
| R&D expenses *1 | | | | 48.5 |
| Others (core basis) *2 | | | | 13.7 |
| **Core operating profit** | | | | **43.2** |

*1 R&D expenses are controlled globally and not allocated to each segment.

*2 Including P/L on business transfers and share of P/L of associates accounted for using equity method.

## IV. Revenue Information

### 1. Revenue by segment

(Billions of JPY)

| Segment | FY2024 | **FY2025** | Change | Change % |
|---|---|---|---|---|
| Japan | 99.8 | **92.4** | (7.5) | (7.5) |
| North America | 251.8 | **337.9** | 86.1 | 34.2 |
| Asia | 47.2 | **23.0** | (24.2) | (51.2) |
| Total | 398.8 | **453.3** | 54.5 | 13.7 |

### 2. Revenue by Region

(Billions of JPY)

| Segment | **FY2025** | FY2026 (Forecasts) | Change | Change % |
|---|---|---|---|---|
| Japan | 83.4 | **87.6** | 4.2 | 5.1 |
| U.S. | 321.8 | **406.4** | 84.6 | 26.3 |
| Other | 48.1 | **46.0** | (2.1) | (4.3) |
| Total | 453.3 | **540.0** | 86.7 | 19.1 |

### 3. Revenue of Major Products (1)

(Invoice price basis, Billions of JPY)

| Brand name<br>Therapeutic indication | FY2024 | **FY2025** | Change | Change % | FY2026 (Forecasts) |
|---|---|---|---|---|---|
| **Japan** | | | | | |
| **XEPLION®/XEPLION TRI®**<br>Long-acting injectable antipsychotics<br>(Jan. 2026～) | — | **3.2** | 3.2 | — | 17.1 |
| **LATUDA®**<br>Atypical antipsychotic | 13.2 | **13.7** | 0.5 | 4.1 | 13.6 |
| **TWYMEEG®**<br>Therapeutic agent for type 2 diabetes<br>(Sep. 2021～) | 7.6 | **10.6** | 3.0 | 39.0 | 11.9 |
| **METGLUCO®**<br>Therapeutic agent for type 2 diabetes | 7.3 | **7.4** | 0.1 | 1.3 | 7.6 |
| **Equa®/EquMet®**<br>Therapeutic agent for type 2 diabetes | 24.9 | **8.7** | (16.2) | (64.9) | — |
| **LONASEN® Tape**<br>Atypical antipsychotic | 4.6 | **5.0** | 0.4 | 8.2 | 4.4 |
| **Authorized Generics** | 11.4 | **12.1** | 0.7 | 5.9 | 11.2 |

### 3. Revenue of Major Products (2)

(Billions of JPY)

| Brand name<br>Therapeutic indication | FY2024 | **FY2025** | Change | Change % | FY2026 (Forecasts) |
|---|---|---|---|---|---|
| **U.S.** | | | | | |
| **ORGOVYX®**<br>Therapeutic agent for advanced prostate cancer (Jan. 2021～) | 83.1 | **155.0** | 71.9 | 86.6 | 209.9 |
| **MYFEMBREE®**<br>Therapeutic agent for uterine fibroids and endometriosis<br>(Jun. 2021～/Aug. 2022～) | 12.8 | **14.4** | 1.6 | 12.6 | 15.4 |
| **GEMTESA®**<br>Therapeutic agent for overactive bladder (Apr. 2021～) | 65.8 | **96.0** | 30.2 | 46.0 | 106.3 |
| **RETHYMIC®**<br>Cultured thymus tissue for pediatric congenital athymia (Mar. 2022～) | 6.8 | **6.3** | (0.5) | (7.1) | 5.4 |
| **APTIOM®**<br>Antiepileptic | 39.4 | **14.9** | (24.5) | (62.1) | 5.4 |

**(Ref.) Products sales in U.S. (based on local currency)**

(Millions of USD)

| Brand name | FY2024 | **FY2025** | Change | Change % | FY2026 (Forecasts) |
|---|---|---|---|---|---|
| ORGOVYX® | 544 | **1,029** | 484 | 89.0 | 1,354 |
| MYFEMBREE® | 84 | **96** | 12 | 14.1 | 100 |
| GEMTESA® | 431 | **637** | 206 | 47.9 | 686 |
| RETHYMIC® | 45 | **42** | (3) | (6.5) | 35 |
| APTIOM® | 258 | **99** | (159) | (61.6) | 35 |

## V. Gross Profit by Region (Core Basis)

(Billions of JPY)

| FY2026 Forecasts | Japan | U.S. | Other | Total |
|---|---|---|---|---|
| Revenue | 87.6 | 406.4 | 46.0 | 540.0 |
| Cost of sales | 52.1 | 152.7 | 40.2 | 245.0 |
| Gross profit | 35.5 | 253.7 | 5.8 | 295.0 |

(Billions of JPY)

| FY2025 Results | Japan | U.S. | Other | Total |
|---|---|---|---|---|
| Revenue | 83.4 | 321.8 | 48.1 | 453.3 |
| Cost of sales | 43.7 | 123.2 | 29.5 | 196.4 |
| Gross profit | 39.6 | 198.7 | 18.6 | 256.9 |

## VI. Consolidated Statement of Financial Position

(Billions of JPY)

| | Mar. 31 2025 | Mar. 31 2026 | Change |
|---|---|---|---|
| **Assets** | **742.6** | **804.6** | **62.0** |
| **Non-current assets** | **489.4** | **525.3** | **35.9** |
| **Property, plant and equipment** | 46.6 | **44.2** | (2.4) |
| **Goodwill** | 197.4 | **211.1** | 13.7 |
| **Intangible assets** | 172.5 | **160.5** | (12.0) |
| Patent rights/Marketing rights | 167.7 | **155.9** | (11.8) |
| In-process R&D | 0.5 | **0.7** | 0.2 |
| Others | 4.4 | **3.9** | (0.5) |
| **Other financial assets** | 44.1 | **44.7** | 0.6 |
| **Other non-current assets** | 28.2 | **64.4** | 36.2 |
| **Deferred tax assets** | 0.5 | **0.4** | (0.1) |
| **Current assets** | **253.2** | **279.3** | **26.1** |
| **Inventories** | 94.2 | **85.4** | (8.8) |
| **Trade and other receivables** | 74.8 | **131.4** | 56.6 |
| **Other financial assets** | 16.8 | **5.3** | (11.5) |
| **Other current assets** | 13.8 | **12.8** | (1.0) |
| **Cash and cash equivalents** | 23.1 | **44.3** | 21.2 |
| **Assets held for sale** | 30.4 | **—** | (30.4) |
| **Liabilities** | **573.1** | **512.1** | **(61.0)** |
| **Non-current liabilities** | **332.5** | **240.6** | **(91.9)** |
| **Bonds and borrowings** | 259.0 | **179.1** | (79.9) |
| **Other financial liabilities** | 15.8 | **16.6** | 0.7 |
| **Retirement benefit liabilities** | 6.5 | **5.7** | (0.9) |
| **Other non-current liabilities** | 24.6 | **23.5** | (1.2) |
| **Deferred tax liabilities** | 26.6 | **15.8** | (10.7) |
| **Current liabilities** | **240.6** | **271.5** | **30.9** |
| **Borrowings** | 46.4 | **38.1** | (8.3) |
| **Trade and other payables** | 38.5 | **56.7** | 18.2 |
| **Other financial liabilities** | 32.9 | **35.2** | 2.3 |
| **Income taxes payable** | 1.6 | **1.1** | (0.5) |
| **Provisions** | 72.0 | **89.6** | 17.6 |
| **Other current liabilities** | 45.7 | **50.8** | 5.1 |
| **Liabilities directly associated with assets held for sale** | 3.5 | **—** | (3.5) |
| **Equity** | **169.5** | **292.5** | **123.0** |
| **Share capital** | 22.4 | **22.4** | — |
| **Treasury shares** | (0.7) | **(0.7)** | (0.0) |
| **Retained earnings** | 46.8 | **159.0** | 112.2 |
| **Other components of equity** | 97.5 | **111.8** | 14.2 |
| **Other comprehensive income associated with assets held for sale** | 3.5 | **—** | (3.5) |
| **Equity attributable to owners of the parent** | **169.5** | **292.5** | **123.0** |

| **Major patent rights** | 25/3 | 26/3 |
|---|---|---|
| ORGOVYX® (relugolix) | 63.8 | 59.9 |
| MYFEMBREE® (relugolix) | 9.7 | 9.1 |
| GEMTESA® (vibegron) | 92.2 | 88.4 |

← Increase in investments accounted for using the equity method

← Increase in accounts receivable due to sales growth, etc.

← Repayment of long-term borrowings

← Reversal of deferred tax liabilities due to assignment of intangible assets within our group

← Repayment of short-term borrowings, etc.

← Increase in provisions due to sales growth, etc.

## VII. Changes in Quarterly Results

### 1. Consolidated Statement of Profit or Loss (Core Basis)

(Billions of JPY)

| | FY2024 | | | | FY2025 | | | |
|---|---|---|---|---|---|---|---|---|
| | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 |
| **Revenue** | **90.7** | **90.1** | **112.4** | **105.6** | **108.0** | **119.1** | **120.6** | 105.5 |
| Cost of sales | 34.9 | 37.3 | 41.3 | 39.7 | 44.1 | 45.6 | 55.4 | 51.3 |
| Gross profit | 55.7 | 52.8 | 71.2 | 66.0 | 63.9 | 73.5 | 65.2 | 54.3 |
| SG&A expenses | 43.8 | 39.6 | 41.0 | 43.3 | 35.4 | 38.6 | 42.5 | 42.9 |
| R&D expenses | 12.8 | 12.3 | 10.2 | 13.1 | 8.1 | 9.4 | 10.4 | 16.1 |
| Others (core basis) | (0.0) | (0.0) | 1.7 | 12.1 | (0.1) | 50.1 | 1.0 | 1.2 |
| **Core operating profit (loss)** | **(0.9)** | **0.9** | **21.6** | **21.6** | **20.4** | **75.7** | **13.4** | (3.5) |
| Adjustments (negative number indicates net expense) | (2.2) | (5.9) | (0.2) | (6.1) | 0.0 | 0.0 | 0.3 | 1.1 |
| **Operating profit (loss)** | **(3.1)** | **(5.1)** | **21.4** | **15.6** | **20.4** | **75.8** | **13.6** | (2.4) |
| **Net profit (loss) attributable to owners of the parent** | **15.9** | **(48.2)** | **53.4** | **2.4** | **11.2** | **87.7** | **8.8** | (0.8) |

### 2. Revenue of Major Products

| | FY2024 | | | | FY2025 | | | |
|---|---|---|---|---|---|---|---|---|
| | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 |
| **Japan** | | | | | | | | (Invoice price basis, Billions of JPY) |
| **XEPLION®/XEPLION TRI®** | — | — | — | — | — | — | — | 3.2 |
| **LATUDA®** | 3.4 | 3.3 | 3.6 | 2.9 | 3.5 | 3.4 | 3.8 | 3.0 |
| **TWYMEEG®** | 1.7 | 1.8 | 2.1 | 1.9 | 2.4 | 2.6 | 2.9 | 2.7 |
| **METGLUCO®** | 1.9 | 1.9 | 1.9 | 1.7 | 1.9 | 1.8 | 2.0 | 1.7 |
| **Equa®/EquMet®** | 7.4 | 6.8 | 6.8 | 4.0 | 4.2 | 3.3 | 1.2 | 0.0 |
| **LONASEN® Tape** | 1.1 | 1.2 | 1.3 | 1.0 | 1.2 | 1.2 | 1.4 | 1.1 |
| **Authorized Generics** | 2.8 | 2.7 | 3.2 | 2.7 | 3.1 | 3.0 | 3.3 | 2.8 |
| **Export products, One-time revenue, Others** | 8.7 | 8.2 | 6.7 | 7.2 | 6.9 | 8.4 | 7.7 | 8.6 |
| **North America** | | | | | | | | (Millions of USD) |
| **ORGOVYX®** | 108 | 125 | 146 | 166 | 226 | 247 | 304 | 252 |
| **MYFEMBREE®** | 19 | 20 | 26 | 18 | 20 | 24 | 30 | 22 |
| **GEMTESA®** | 78 | 87 | 118 | 148 | 147 | 150 | 189 | 151 |
| **RETHYMIC®** | 11 | 8 | 14 | 11 | 6 | 17 | 8 | 11 |
| **APTIOM®** | 65 | 65 | 69 | 59 | 49 | 24 | 11 | 15 |
| **Export products, One-time revenue, Others** | 52 | 43 | 120 | 73 | 54 | 150 | 75 | 64 |

## VIII. Major Group Companies (As of March 31, 2026)

| Domestic | Establish-ment | Ownership | Number of employees | Businesses |
|---|---|---|---|---|
| **Sumitomo Pharma Promo Co., Ltd.** | 1998/ 6 | 100% | 25 | Manufacturing and sales of pharmaceuticals |
| **Marubeni Pharmaceuticals Corporation*1** | 2025/ 5 | 40.0% | — | Manufacturing and sales of pharmaceuticals and others |
| **RACTHERA Co., Ltd. *1** | 2024/11 | 33.4% | — | Research and development of regenerative medicine –related products |
| **S-RACMO Co., Ltd. *1** | 2020/ 9 | 33.4% | — | Contract development and manufacturing services in the field of regenerative and cellular medicine |
| **Overseas** | Establish-ment | Ownership | Number of employees | Businesses |
| **Sumitomo Pharma America, Inc.** | 1984/ 1 | 100% | 1,225 *2 | Manufacturing and sales of pharmaceuticals |

*1 Associates

*2 Include employees of consolidated subsidiaries

**(Reference)**

| **Number of employees** | March 31, 2024 | | March 31, 2025 | | **March 31, 2026** | |
|---|---|---|---|---|---|---|
| **consolidated / non-consolidated** | 4,980 | 2,908 | 3,832 | 1,799 | **3,123** | **1,747** |
| **Number of MRs** (approx., include contracted MRs) | | | | | | |
| **Japan** Exclude managers/Total | 910 | 1,000 | 390 | 450 | **460** | **510** |
| **U.S.** Exclude managers/Total | 430 | 490 | 380 | 430 | **390** | **440** |

## IX. Shareholder Positioning (As of March 31, 2026)

**1. Total number of authorized shares:** 1,500,000,000

**2. Total number of shares outstanding:** 397,900,154 (Including number of treasury stock 611,105)

**3. Number of shareholders by category:**

| Shareholder category | Number of shareholders | Number of shares (Thousands) | Percentage of total (%) |
|---|---|---|---|
| Financial institutions | 24 | 50,998 | 12.82 |
| Securities companies | 61 | 8,138 | 2.05 |
| Other Japanese corporations | 569 | 216,469 | 54.4 |
| Corporations outside Japan, etc. | 1,302 | 56,550 | 14.21 |
| Individuals and others (Including treasury stock) | 107,234 | 65,743 | 16.52 |
| Total | 109,190 | 397,900 | 100.00 |

Note: The numbers of shares are rounded down to the nearest thousand shares.

**4. Major shareholders:**

| Shareholders | Number of shares held (Thousands) | Percentage of shareholding(%) |
|---|---|---|
| Sumitomo Chemical Co., Ltd. | 205,634 | 51.76 |
| The Master Trust Bank of Japan, Ltd. (Trust account) | 25,038 | 6.30 |
| SMBC Trust Bank Ltd. (Trust account for Sumitomo Mitsui Banking Corporation's retirement benefits) | 7,000 | 1.76 |
| Custody Bank of Japan, Ltd. (Trust account) | 6,219 | 1.57 |
| Sumitomo Life Insurance Company | 5,776 | 1.45 |
| BNYM AS AGT/CLTS 10 PERCENT | 4,573 | 1.15 |
| Inabata & Co., Ltd. | 4,400 | 1.11 |
| THE BANK OF NEW YORK, TREATY JASDEC ACCOUNT | 3,977 | 1.00 |
| Nippon Life Insurance Company | 3,790 | 0.95 |
| J.P. MORGAN BANK LUXEMBOURG S.A. 381593 | 3,030 | 0.76 |

Notes: 1: Percentage of shareholding is calculated excluding treasury stock (611,105 shares*).
*Exclude 1,000 shares under name of the Company which are not owned by the Company substantially.
2: The numbers of shares held are rounded down to the nearest thousand shares.

**X . Development Pipeline (As of May 13, 2026)**

- This table shows key clinical studies for indications of products for which the Sumitomo Pharma Group aims to obtain regulatory approval.
- The study for the most advanced development stage is listed if there are multiple studies with the same region and indication.
- The development stage is updated based on the date when the relevant Investigational New Drug Application/amended IND/ Clinical Trial Notification is filed and/or approved by the applicable authority.

**1. Psychiatry & Neurology**

| Brand name/ Generic name/ Product code | | Planned indication(s) | Development stage |
|---|---|---|---|
| Small molecule | LATUDA®/ Lurasidone hydrochloride | (New dosage and administration: pediatric) Schizophrenia | Submitted (March 2026) |
| | DSP-0038 | Alzheimer's disease psychosis | Phase 1 |
| | DSP-0187 | Narcolepsy | Phase 1 |
| | DSP-3456 | Treatment resistant depression | Phase 1 |
| | DSP-0378 | Progressive Myoclonic Epilepsy and Developmental Epileptic Encephalopathy | Phase 1 |
| | DSP-2342 | To be determined | Phase 1 |
| | DSP-0551 | Tremor associated with Parkinson's disease | Phase 1 |
| Regenerative medicine / cell therapy (Collaboration with RACTHERA Co., Ltd.) | AMCHEPRY®/Raguneprocel /CT1-DAP001/DSP-1083 (Allogeneic iPS [induced pluripotent stem] cell-derived dopaminergic neural progenitor cells) (JAPAN) | Parkinson's disease | Conditional and time-limited approval (March 2026)<br>Post-marketing clinical study |
| | Raguneprocel /CT1-DAP001/DSP-1083 (Allogeneic iPS cell-derived dopaminergic neural progenitor cells) (U.S.) | Parkinson's disease | Phase 1/2 (Investigator-initiated study) |
| | | | Phase 1/2 （Company-sponsored clinical study） |
| | HLCR011 (Allogeneic iPS cell-derived retinal pigment epithelial cells) (JAPAN) | Retinal pigment epithelium tear | Phase 1/2 |
| | DSP-3077 （Allogeneic iPS cell-derived | Retinitis pigmentosa | Phase 1/2 |

| | | | |
|---|---|---|---|
| | retinal sheet）(U.S.) | | |

**2. Oncology**

| Brand name/<br>Generic name/<br>Product code | Planned indication(s) | Development stage |
|---|---|---|
| Enzomenib | Acute leukemia | Phase 2 |
| Nuvisertib | Myelofibrosis | Phase 1/2 |
| SMP-3124 | Solid tumors | Phase 1/2 |
| DSP-0390 | Glioblastoma | Phase 1 |

**3. Others**

| Brand name/<br>Generic name/<br>Product code | Planned indication(s) | Development stage |
|---|---|---|
| KSP-1007 | Complicated urinary tract infections and complicated intra-abdominal infections, hospital-acquired bacterial pneumonia including ventilator-associated bacterial pneumonia | Phase 1 |
| fH1/DSP-0546LP | Influenza virus prophylaxis | Phase 1 |

【Main revisions since the previous announcement of January 2026】

| Brand name/<br>Generic name/<br>Product code | Planned indication(s) | Development stage | Updates |
|---|---|---|---|
| AMCHEPRY®/Ragunepr oce l /CT1-DAP001 / DSP-1083 (Japan) | Parkinson's disease | Post-marketing clinical study | Conditional and time-limited approval obtained (March 2026) |
| DSP-0551 | Tremor associated with Parkinson's disease | Phase 1 | Phase 1 initiation |

**XI. Profiles of Major Products under Development (As of May 13, 2026)**

**1. Psychiatry & Neurology**

**(Small molecule)**

**DSP-0038** Origin: in-house (Joint research with Recursion (formerly Exscientia Ltd.)), Formulation: oral

- Planned indication: Alzheimer's disease psychosis
- DSP-0038 is a novel compound discovered at Sumitomo Pharma using Recursion's AI technologies. DSP-0038 is a serotonin 5-$HT_{2A}$ receptor antagonist and a serotonin 5-$HT_{1A}$ receptor agonist. DSP-0038 is expected to demonstrate a greater antipsychotic effect, based on the additive effect of 5-$HT_{2A}$ receptor antagonist and 5-$HT_{1A}$ receptor agonist. The compound could also have broader efficacy in the treatment of behavioral and psychological symptoms of dementia (BPSD) which include agitation, aggression, anxiety, and depression. Furthermore, DSP-0038 has negligible affinity for dopamine $D_2$ receptors, and therefore it can be expected to show improved safety and tolerability compared to existing antipsychotics.

**DSP-0187** Origin: in-house, Formulation: oral

- Planned indication: Narcolepsy
- DSP-0187 is an orexin 2 receptor agonist. It is expected to improve excessive daytime sleepiness (EDS) and cataplexy of narcolepsy caused by orexin deficiency. DSP-0187 is also expected to demonstrate efficacy in EDS (Excessive Daytime Sleepiness) conditions other than narcolepsy.

**DSP-3456** Origin: in-house, Formulation: oral

- Planned indication: Treatment resistant depression
- DSP-3456 is a metabotropic glutamate receptor 2/3 negative allosteric modulator (mGluR2/3 NAM). DSP-3456 is expected to exhibit a ketamine-like antidepressant effect through selective activation of the prefrontal cortex by enhancing the glutamate release, while avoiding side effects (psychotic symptoms, cognitive dysfunction).

**DSP-0378** Origin: in-house, Formulation: oral

- Planned indications: Progressive Myoclonic Epilepsy and Developmental Epileptic Encephalopathy
- DSP-0378 is a gamma-aminobutyric acid $(GABA)_A$ receptor positive allosteric modulator. DSP-0378 acts on various subtypes of $GABA_A$ receptors expressed in synaptic and extrasynaptic regions in a manner different from common $GABA_A$ receptor potentiators such as benzodiazepines and neurosteroids. DSP-0378 is expected to exhibit an antiepileptic effect against broad epilepsies including Progressive Myoclonic Epilepsy and Developmental Epileptic Encephalopathy.

**DSP-2342** Origin: in-house (Joint research with Recursion (formerly Exscientia Ltd.)), Formulation: oral

- Planned indication: TBD
- DSP-2342 is a novel compound discovered at Sumitomo Pharma using Recursion's AI technologies. DSP-2342 is a serotonin 5-$HT_{2A}$ and 5-$HT_7$ receptor antagonist. DSP-2342 is expected to demonstrate a broader antipsychotic effect in psychosis, anxiety, and depression, based on the additive effect of 5-$HT_{2A}$ and 5-$HT_7$ receptor antagonist. Furthermore, DSP-2342 has high selectivity for 5-$HT_{2A}$ and 5-$HT_7$ receptors, so is expected to show a high level of safety and tolerability.

**DSP-0551** Origin: in-house, Formulation: oral

- Planned indication: Tremor associated with Parkinson's disease
- DSP-0551 is a multi-ion channel modulator identified through phenotype-based drug discovery and exhibits inhibitory activity against multiple T-type calcium and sodium ion channels that have been implicated in tremor. Through these mechanisms, DSP-0551 is expected to modulate abnormal neuronal firing and excessive synchronization in neural circuits associated with tremor, thereby improving tremor associated with Parkinson's disease.

**(Regenerative medicine / cell therapy (Collaboration with RACTHERA Co., Ltd.))**

In collaboration with RACTHERA Co., Ltd., and our partners in the industry-academia collaboration, we are developing allogeneic iPS cell-derived products using iPS cells from healthy donors for the treatment of Parkinson's disease, RPE (retinal pigment epithelium) tear, AMD (age-related macular degeneration), retinitis pigmentosa, and spinal cord injury.

**CT1-DAP001/DSP-1083 (Allogeneic iPS cell-derived dopaminergic neural progenitor cells)**

- Partnering: Kyoto University CiRA, UC San Diego
- Planned indication: Parkinson's disease
- In Japan, the Ministry of Health, Labour and Welfare (MHLW) granted CT1-DAP001/DSP-1083 "Sakigake Designation Scheme" status as a regenerative medicine & cell therapy in February 2017 and Orphan Regenerative Medical Product Designation in December 2025 for the indication of Parkinson's disease. In addition, CT1-DAP001/DSP-1083 obtained manufacturing and marketing approval in Japan under the conditional and time-limited approval framework in March 2026.

- In the U.S., an investigator-initiated clinical study is being conducted at the UC San Diego, while company-sponsored studies are also being pursued in parallel.

**HLCR011 (Allogeneic iPS cell-derived retinal pigment epithelial cells)**

- Partnering: HEALIOS K.K.
- Planned indication: Retinal pigment epithelium tear

**DSP-3077 (Allogeneic iPS cell-derived retinal sheet)**

- Partnering: Massachusetts Eye and Ear in Boston, Massachusetts (Teaching hospital of Harvard Medical School), USA
- Planned indication: Retinitis pigmentosa
- The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for the indication of retinitis pigmentosa in March 2026.

## 2. Oncology

**Enzomenib** Origin: in-house (Joint research with Kyoto University), Formulation: oral

- Planned indication: Acute leukemia
- Enzomenib (DSP-5336) is a small molecule inhibitor of the menin and lysine methyltransferase 2A (KMT2A) protein interaction. Acute myeloid leukemia with KMT2A rearrangement or nucleophosmin 1 (NPM1) mutation relies on the menin-KMT2A interaction for upregulation of genes instrumental to leukemogenesis. Enzomenib has been shown to have anti-cancer activity through downregulation of these genes by inhibition of menin-KMT2A interaction in preclinical studies. The FDA granted Orphan Drug Designation for enzomenib for the indication of acute myeloid leukemia in June 2022 and granted Fast Track Designation for the treatment of relapsed or refractory acute myeloid leukemia with KMT2A rearrangement or NPM1 mutation in June 2024. Furthermore, the MHLW granted Orphan Drug Designation for enzomenib for the indication of relapsed or refractory acute myeloid leukemia with KMT2A rearrangement or NPM1 mutation in September 2024.

**Nuvisertib** Origin: in-house (former Tolero Pharmaceuticals, Inc.), Formulation: oral

- Planned indication: Myelofibrosis
- Nuvisertib (TP-3654) inhibits the inflammatory signaling pathways through inhibition of PIM1 (proviral integration site for Moloney murine leukemia virus 1) kinase. PIM1 kinase is frequently overexpressed in various hematologic malignancies and solid tumors, allowing cancer cells to evade apoptosis and promoting tumor growth. The FDA, the MHLW, and the European Medicines Agency (EMA) granted Orphan Drug Designation for nuvisertib for the indication of myelofibrosis in May 2022, November 2024, and July 2025, respectively. Additionally, the FDA granted nuvisertib Fast Track Designation in June 2025, also for the indication of myelofibrosis.

**SMP-3124** Origin: in-house, Formulation: injection (Liposomal Nanomedicine)

- Planned indication: Solid tumors
- SMP-3124 is an injection including a liposome-encapsulated CHK1 (checkpoint kinase 1) inhibitor. CHK1 is activated by the DNA damage response, leading to cell-cycle arrest, and DNA repair via serine-threonine kinase. CHK1 inhibition leads cancer cells with high replication stress to apoptosis by inducing further DNA damage. SMP-3124 is expected to strengthen the anti-tumor activity and attenuate side effects of the CHK1 inhibitor by changing pharmacokinetics of the compound with liposomal nanomedicinal encapsulation.

**DSP-0390** Origin: in-house, Formulation: oral

- Planned indication: Glioblastoma
- DSP-0390 is an inhibitor of Emopamil Binding Protein (EBP), an endoplasmic reticulum membrane protein involved in cholesterol biosynthesis. EBP mediates de novo cholesterol synthesis for cell membrane structure and signaling, enabling aberrant growth of tumors. Inhibition of EBP causes depletion of cellular cholesterol, which is expected to lead to anti-cancer activity. The FDA granted Orphan Drug Designation for DSP-0390 for the indication of brain cancer in May 2022.

### 3. Others

**KSP-1007** Origin: in-house (Joint research with The Kitasato Institute), Formulation: injection

- Planned indications: Complicated urinary tract and intra-abdominal infections, hospital-acquired bacterial pneumonia including ventilator-associated bacterial pneumonia
- KSP-1007 broadly and strongly inhibits β-lactamases, enzymes produced by bacteria that can degrade carbapenem antibiotics. KSP-1007 is expected to become an effective treatment option against carbapenem-resistant bacterial infections as a component of a combination drug with meropenem hydrate, a carbapenem antibiotic in general use worldwide (name of Sumitomo Pharma's product for the Japanese market: MEROPEN®). The FDA granted Qualified Infectious Disease Product (QIDP) status and Fast Track Designation for KSP-1007 for the indications of complicated urinary tract infections, complicated intra-abdominal infections, and hospital-acquired bacterial pneumonia including ventilator-associated bacterial pneumonia in August 2022.

**fH1/DSP-0546LP** Origin: in-house (Joint research with the National Institutes of Biomedical Innovation, Health and Nutrition), Formulation: injection

- Planned indication: Influenza virus prophylaxis
- fH1/DSP-0546LP is a next-generation candidate vaccine formulation composed of the post-fusion hemagglutinin antigen (fH1) that is expected to be effective against a broad range of influenza viruses, and TLR7 adjuvant "DSP-0546LP" that enhances the quantity, quality, and durability of immune responses. Conventional influenza vaccines lose effectiveness due to viral mutations, making it necessary to select, produce, and inoculate a vaccine to immunize against strains predicted to circulate each year. They may also not respond well to emerging strains of influenza.
- The pre-clinical study of fH1/DSP-0546LP demonstrated broad cross protection against influenza viruses antigenically different from those used in vaccine formulations, and the significance of the TLR7 adjuvant, DSP-0546LP. It is expected that fH1/DSP-0546LP will improve the breadth and durability of protection against seasonal influenza viruses and will be effective against novel and potentially pandemic strains.